The brand of the Novo Nordisk insulin brand will continue to be unexpected in road, clarified the Danish health company, even when its feather filling.
The feather filling is being eliminated as part of the consolidation or its global manufacturing network, the company said, a process that is expected to be complete at the end of 2025.
While the multinational had said at the end of last year, it was discontinuing some of the previous generation versions of veteran insulin diabetologists said that the people who need insulin still had optionable multiple in the country.
The Diabetologist V Mohan said that people who used the pencil device more expectation could change to a general insulin that was available from the company; Vials or other similar products of other competitions, including local competitions such as Lupin, Eris LifeScience, etc.
Mixtard fillings were popular for their convenience, however, more exenous than vials, said Mohan, president of Dr. Mohan’s Diabetes Specialties Center, Chennai. Those who could pay the product could speak with their doctors and change to a similar product, while those who could pay the roads would not be affected, he said.
Responding to a Business line Query, Novonordisk said: “We want to clarify that we are discontinuing Mixtard in India and will continue to be Avia Will. Together with her, another form of insulinas, including the human insulins of Novo Nordisk Forpable.” The company added that it was consolidating its inspletion to create space in its global manufacturing network. And “in this process, we are eliminating the filling of the pen,” he added.
Recognizing the interruption that this decision could cause, he said, “we strive to leave no patients without alternative treatment options, whether from Novo Nordisk or other companies.” The company said it was working with health authorities, health professionals, commercial partners and patients in the transition to other treatments.
Posted on April 22, 2025